Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, PR. China.
Expert Rev Anticancer Ther. 2021 Oct;21(10):1097-1104. doi: 10.1080/14737140.2021.1944108. Epub 2021 Jul 14.
: Metastatic (m) colorectal cancer (CRC) can be divided into specific subgroups under the 'one gene, one drug' paradigm of precision medicine. Progress of targeted therapy in mCRC patients significantly improved the overall survival rate, notably by therapy targeting of EGFR signaling in RAS wild-type mCRC patients. Activation of the HER2 pathway is an important mechanism of resistance for anti-EGFR therapy.: Inhibition of HER2 with monoclonal antibodies and/or tyrosine kinase inhibitors induces tumor responses in partial HER2-positive CRC refractory to standard systemic therapy. This manuscript aimed to provide an overall insight of the HER2 expression pattern and highlighted specific clinicopathological and molecular features involved in mCRC. In addition, we summarize preclinical and clinical trials in HER2-positive mCRC.: The status and progression of HER2-positive gastric cancer and breast cancer and anti-HER2 therapy have been reported widely. However, the understanding of HER2-positive CRC models which may guide future therapeutic decision-making is poor. Therefore, it is essential to summarize the existing research to extract similarity and difference among various studies.
转移性（m）结直肠癌（CRC）可以根据精准医学的“一个基因，一种药物”范式分为特定亚组。mCRC 患者的靶向治疗进展显著提高了总体生存率，特别是通过针对 RAS 野生型 mCRC 患者的 EGFR 信号的治疗。HER2 通路的激活是抗 EGFR 治疗产生耐药性的重要机制。用单克隆抗体和/或酪氨酸激酶抑制剂抑制 HER2 可诱导对标准系统治疗耐药的部分 HER2 阳性 CRC 产生肿瘤反应。本文旨在全面了解 HER2 表达模式，并强调涉及 mCRC 的特定临床病理和分子特征。此外，我们总结了 HER2 阳性 mCRC 的临床前和临床试验。HER2 阳性胃癌和乳腺癌的状态和进展以及抗 HER2 治疗已广泛报道。然而，对可能指导未来治疗决策的 HER2 阳性 CRC 模型的理解很差。因此，总结现有研究以提取各种研究之间的相似性和差异非常重要。
